OBJECTIVE: Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group. This report describes the use of Citalopram in comparison with Fluoxetine in childhood-onset OCD. METHOD: This study is a randomized, double blind, fixed-does (20mg) trial of Fluoxetine versus Citalopram in 29 children and adolescents (17 boys and 12 girls) with OCD, aged 7-18 years (mean 13.8 and SD 3.05). The length of study was 6 weeks. Obsessive-Compulsive symptom severity was measured by Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) and Clinician's Global Impression Scale (CGI). DICA (Diagnostic Interview of Children and Adolescents) was used to diagnose the psychiatric disorders. RESULTS: Each group showed significant improvement over the baseline as measured by the CY-BOCS (p < 0.01) but not by CGI (p = NS). The Comparison between two groups showed no significant differences in efficacy and safety of the drugs. Most common adverse effects were headache for Citalopram and tremor for Fluoxetine. CONCLUSION: The results suggest that Citalopram is as safe and effective as Fluoxetine for children and adolescents with OCD. Further studies are needed to replicate our findings.
RCT Entities:
OBJECTIVE: Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group. This report describes the use of Citalopram in comparison with Fluoxetine in childhood-onset OCD. METHOD: This study is a randomized, double blind, fixed-does (20mg) trial of Fluoxetine versus Citalopram in 29 children and adolescents (17 boys and 12 girls) with OCD, aged 7-18 years (mean 13.8 and SD 3.05). The length of study was 6 weeks. Obsessive-Compulsive symptom severity was measured by Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) and Clinician's Global Impression Scale (CGI). DICA (Diagnostic Interview of Children and Adolescents) was used to diagnose the psychiatric disorders. RESULTS: Each group showed significant improvement over the baseline as measured by the CY-BOCS (p < 0.01) but not by CGI (p = NS). The Comparison between two groups showed no significant differences in efficacy and safety of the drugs. Most common adverse effects were headache for Citalopram and tremor for Fluoxetine. CONCLUSION: The results suggest that Citalopram is as safe and effective as Fluoxetine for children and adolescents with OCD. Further studies are needed to replicate our findings.
Authors: L Scahill; M A Riddle; M McSwiggin-Hardin; S I Ort; R A King; W K Goodman; D Cicchetti; J F Leckman Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-06 Impact factor: 8.829
Authors: M F Flament; A Whitaker; J L Rapoport; M Davies; C Z Berg; K Kalikow; W Sceery; D Shaffer Journal: J Am Acad Child Adolesc Psychiatry Date: 1988-11 Impact factor: 8.829
Authors: M A Riddle; L Scahill; R King; M T Hardin; K E Towbin; S I Ort; J F Leckman; D J Cohen Journal: J Am Acad Child Adolesc Psychiatry Date: 1990-09 Impact factor: 8.829
Authors: M A Riddle; L Scahill; R A King; M T Hardin; G M Anderson; S I Ort; J C Smith; J F Leckman; D J Cohen Journal: J Am Acad Child Adolesc Psychiatry Date: 1992-11 Impact factor: 8.829
Authors: Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker Journal: BMC Psychiatry Date: 2014-07-02 Impact factor: 3.630
Authors: Danielle Ung; Jeffrey J Wood; Jill Ehrenreich-May; Elysse B Arnold; Cori Fuji; Patricia Renno; Tanya K Murphy; Adam B Lewin; P Jane Mutch; Eric A Storch Journal: Neuropsychiatry (London) Date: 2013-04
Authors: Vijaya Padma Kotapati; Ali M Khan; Sara Dar; Gulshan Begum; Ramya Bachu; Mahwish Adnan; Aarij Zubair; Rizwan A Ahmed Journal: Front Psychiatry Date: 2019-08-06 Impact factor: 4.157